Richard J. Benjamin - 03 Mar 2025 Form 4 Insider Report for CERUS CORP (CERS)

Role
Chief Medical Officer
Signature
Richard J. Benjamin, by Chrystal N. Jensen, attorney-in-fact
Issuer symbol
CERS
Transactions as of
03 Mar 2025
Net transactions value
-$90,571
Form type
4
Filing time
05 Mar 2025, 20:23:08 UTC
Previous filing
28 Feb 2025
Next filing
10 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERS Common Stock Options Exercise +13,912 +3.2% 451,919 03 Mar 2025 Direct F1
transaction CERS Common Stock Sale $80,828 -51,254 -11% $1.58 400,665 03 Mar 2025 Direct F2, F3
transaction CERS Common Stock Sale $9,743 -6,292 -1.6% $1.55 394,373 04 Mar 2025 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERS Restricted Stock Unit Options Exercise -13,912 -100% 0 03 Mar 2025 Common Stock 13,912 Direct F1, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Cerus Common Stock.
F2 This transaction was executed pursuant to a 10b5-1 plan.
F3 The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.525 to $1.67 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth.
F4 Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person.
F5 The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.49 to $1.59 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth.
F6 Reflects restricted stock units earned upon satisfaction of certain performance criteria in connection with a performance-based award previously granted by the Issuer.
F7 Not applicable.